clinicaltrialsarena17h
New strategy for Vivoryon as second failed Alzheimer’s trial shows kidney promise
Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.
clinicaltrialsarena17h
New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III
The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.
clinicaltrialsarena18h
Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial
Enanta Pharmaceuticals has reported positive topline outcomes from a Phase II trial of zelicapavir for RSV in paediatric patients.
clinicaltrialsarena19h
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.
clinicaltrialsarena19h
MSD’s trial of combination therapy for ovarian cancer meets primary endpoint
US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ovarian cancer.
clinicaltrialsarena20h
Unmet needs in the chronic hand eczema treatment landscape
While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.
clinicaltrialsarena21h
Sirus Therapeutics announces positive signals from Phase I siRNA trial
The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated in its first-in-human tests.